13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
Autor: | Greg L. Plosker |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Serotype medicine.medical_specialty medicine.disease_cause Pneumococcal Infections Pneumococcal conjugate vaccine Pneumococcal Vaccines Risk Factors Internal medicine Streptococcus pneumoniae medicine Humans Pharmacology (medical) Aged Randomized Controlled Trials as Topic business.industry Immunogenicity Middle Aged Pneumonia Pneumococcal medicine.disease Pneumococcal polysaccharide vaccine Community-Acquired Infections Pneumonia Pneumococcal infections Immunization Immunology business medicine.drug |
Zdroj: | Drugs. 75:1535-1546 |
ISSN: | 1179-1950 0012-6667 |
DOI: | 10.1007/s40265-015-0449-z |
Popis: | The 13-valent pneumococcal conjugate vaccine (Prevenar 13(®), Prevnar 13(®)) [PCV13] consists of 13 serotype-specific polysaccharides of Streptococcus pneumoniae (pneumococcus), each covalently conjugated to a non-toxic immunogenic carrier protein. PCV13 has a well established immunogenicity and tolerability profile in adults, particularly those ≥50 years of age. Results of CAPiTA, a randomized, double-blind, placebo-controlled trial in >84,000 older adults aged ≥65 years, showed that PCV13 was effective in preventing vaccine-type pneumococcal community-acquired pneumonia (CAP), vaccine-type pneumococcal nonbacteraemic (noninvasive) CAP and vaccine-type invasive pneumococcal disease (IPD). These findings, along with changes in pneumococcal serotype distribution and epidemiology of pneumococcal disease, prompted the US Advisory Committee on Immunization Practices (ACIP) to recommend PCV13 in series with 23-valent pneumococcal polysaccharide vaccine (PPVS23) for all adults aged ≥65 years. PCV13 also has a role in preventing pneumococcal disease (pneumonia and IPD) in younger adults with immunocompromising conditions and potentially in those with other underlying medical conditions that increase the risk of pneumococcal disease. |
Databáze: | OpenAIRE |
Externí odkaz: |